Pre-made Utomilumab benchmark antibody ( Whole mAb, anti-TNFRSF9/CD137 therapeutic antibody, Anti-ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-606
Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and a fully human IgG2 agonist monoclonal antibody (mAb) that binds to the extracellular domain of human 4-1BB/CD137 with high affinity and specificity.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6a3w:GH:DE:AB:JK/6mi2:DE:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer|
|Conditions Active||Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer|
|Conditions Discontinued||Non-Hodgkin's lymphoma;Colorectal cancer|
|Development Tech||MorphoSys HuCAL Phage Display|